There was significant growth in annual capacity additions in 2021, a record year for deployment, with more than 200 MW of electrolysis capacity becoming operational.ĭespite promising project announcements, capacity additions slowed down to 130 MW in 2022, with total installed capacity reaching about 690 MW. However, the pace of deployment of electrolysers for dedicated hydrogen production only started to accelerate in the late 2010s. “One year after the declaration of a pandemic by the WHO, we now see that we are on the right track to accomplish our goals.Electrolysers are already widely used in the chlor-alkaline industry to produce chlorine and sodium hydroxide, with installed capacity having reached more than 20 GW. Ugur Sahin, co-founder and CEO of BioNTech, said in the announcement.
“When we started our development last year in January, our aim was to make a difference for people worldwide and to help end this pandemic,” Dr. The analysis also found that the vaccine effectiveness was 94% in preventing asymptomatic Covid-19, where infections show no symptoms. Last week, Pfizer and BioNTech announced that real-world evidence from the Israel Ministry of Health shows that two weeks after the second dose of the vaccine, its effectiveness was at least 97% in preventing symptomatic disease, hospitalizations and death.
The Pfizer/BioNTech vaccine has drawn praise from across the globe for its high effectiveness, with a peer-reviewed study in Israel showing an effectiveness rate of 94% in preventing asymptomatic Covid-19. And that was a strength which helped us along this way.” “As scientists we are used – particularly because we have always worked in technology innovation – we are used to solve problems and unknowns in real time. Türeci also spoke of how a “gender balanced team is one of the key success factors” in BioNTech’s work, boosting in particular the problem solving capabilities of the company. Blueprint clinical trials, whereby the company pre-discusses with regulators the switch in sequence, are also being deployed.Īlthough emerging variants are something BioNTech has to take “seriously,” Türeci told CNN that there is “no reason for fear currently.” The company uses its “fast and adaptable” mRNA platform to exchange the genetic sequence of the old variant against that of the new one, according to Türeci. Single Pfizer vaccine shot provides strong protection for those who've had Covid-19, UK studies suggest (Photo by Frank Augstein / POOL / AFP) (Photo by FRANK AUGSTEIN/POOL/AFP via Getty Images) Frank Augstein/Pool/AFP/Getty Images Britain on December 8 hailed a turning point in the fight against the coronavirus pandemic, as it begins the biggest vaccination programme in the country's history with a new Covid-19 jab. Resources are being directed into being “prepared for tomorrow in case such a variant of concern would occur: the processes with which we can adapt to a new variant,” Türeci added.Ī nurse administers the Pfizer-BioNTech COVID-19 vaccine at Guy's Hospital in London, on December 8, 2020. The company is also being kept busy by the continuous need to test the robustness of their vaccine against new variants of the virus.īased on their analysis, the current vaccine has been found to be effective against the variants first detected in the UK and South Africa, with Türeci stressing that the company’s priority is ascertaining “which variant is of real concern.” In an exclusive interview with CNN, BioNTech co-founder and chief medical officer Özlem Türeci said the company is “continuously reevaluating how the target we have already set could be even overperformed.”ĭespite certain limitations such as the fact that they “cannot train people very fast” the company is focusing on finding partners “who can complement pieces of this pretty large network” of vaccine supply. The makers of the Pfizer/BioNTech coronavirus vaccine are “turning every stone” to scale up production capacity as Europe continues to suffer from a deficit in vaccine supply.
0 kommentar(er)
